Brigatinib/Brigatinib (Embry) is the first generation ALK-targeting drug

Brigatinib/Brigatinib (Brigatinib) is considered a second-generation ALK-targeting drug worldwide. Its research and development background stems from the common resistance problem during the use of the first-generation ALK inhibitor Crizotinib. Since patients with ALK-positive non-small cell lung cancer often develop drug resistance within about a year of treatment, scientists need a drug that can overcome drug-resistant mutations while having better penetration into central nervous system metastases. Therefore, brigatinib was designed and its structure was optimized to enhance its binding ability to the ALK kinase domain, thereby performing better against drug-resistant mutations such as G1202R.

As a second-generation ALK-TKIThe significance of brigatinib lies not only in prolonging the progression-free survival of patients, but also in its clinical value against brain metastases. Multiple overseas studies have pointed out that brigatinib can penetrate the blood-brain barrier and have certain control over brain lesions. This is particularly critical for patients with ALK-positive lung cancer, because brain metastasis is a common and difficult-to-manage progression pattern in clinical practice. In addition, brigatinib's position in the treatment sequence is gradually becoming clearer. It can be used as a second-line drug after crizotinib treatment fails, and it is also recommended by some guidelines as a first-line treatment option.

From the perspective of drug classification,The intergenerational evolution of ALK inhibitors reflects the progress of precision medicine: the first generation mainly laid the foundation for targeted therapy, the second generation is represented by brigatinib and alectinib, which have higher selectivity and wider coverage of resistance mutations, while the third generation lorlatinib further improves the ability to overcome complex resistance mechanisms. Within this framework, brigatinib plays the role of "connecting the past and the next" to help doctors achieve personalized management at different stages of treatment.

With the popularity of molecular testing methods around the world, the clinical value of brigatinib is also reflected in its precise stratified use. Doctors can decide whether brigatinib is a better option based on the patient's type of resistance mutation, previous treatment history, and the presence of brain metastases.

Reference materials:https://www.alunbrig.com/